Sign In
Buy BDX
$170.66
+0.540 (+0.317%)
At Close: Aug 05, 2026
BD to Present at Investor Healthcare Conferences
04:15pm, Thursday, 13'th Feb 2025
FRANKLIN LAKES, N.J. , Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
10:05am, Thursday, 13'th Feb 2025
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching U
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
10:46am, Wednesday, 12'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit
07:19am, Saturday, 08'th Feb 2025
Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.
Compared to Estimates, Becton Dickinson (BDX) Q1 Earnings: A Look at Key Metrics
07:36pm, Wednesday, 05'th Feb 2025
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metric
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
06:55pm, Wednesday, 05'th Feb 2025
Becton Dickinson (BDX) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.68 per share a year ago.
Becton Dickinson looks to separate life sciences unit
04:52pm, Wednesday, 05'th Feb 2025
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.
BD Reports First Quarter Fiscal 2025 Financial Results
04:30pm, Wednesday, 05'th Feb 2025
Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic GAAP and adjusted diluted EPS of $1.0
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
04:30pm, Wednesday, 05'th Feb 2025
Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025
Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings?
12:50pm, Monday, 03'rd Feb 2025
The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory market dynamics.
Insights Into Becton Dickinson (BDX) Q1: Wall Street Projections for Key Metrics
10:21am, Monday, 03'rd Feb 2025
Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared durin
Starboard Value pushes Becton Dickinson to sell life sciences unit, FT reports
07:05am, Monday, 03'rd Feb 2025
Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the medical technology company to sell its life sciences unit, the Financial Times reported on Monday.
Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Thursday, 30'th Jan 2025
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25
04:15pm, Tuesday, 28'th Jan 2025
FRANKLIN LAKES, N.J. , Jan. 28, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has decla
BD Stock Rises on Biosero Deal for AI-Powered Robotic Cytometry Tech
10:50am, Friday, 24'th Jan 2025
BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.
